Idiopathic Pulmonary Fibrosis Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight

The Idiopathic Pulmonary Fibrosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Idiopathic Pulmonary Fibrosis Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Idiopathic Pulmonary Fibrosis Market.

Some of the key takeaways from the Idiopathic Pulmonary Fibrosis Pipeline Report:

• Companies across the globe are diligently working toward developing novel Idiopathic Pulmonary Fibrosis treatment therapies with a considerable amount of success over the years. 
• Idiopathic Pulmonary Fibrosis companies working in the treatment market are Aria Pharmaceuticals, InSilico Medicine, AdAlta, AstraZeneca, Lung Therapeutics, CSL Behring, Galecto Biotech AB, Pliant Therapeutics, Endeavor BioMedicine, FibroGen, Boehringer Ingelheim, and others, are developing therapies for the Idiopathic Pulmonary Fibrosis treatment 
• Emerging Idiopathic Pulmonary Fibrosis therapies such as – TXR 1002, INS018_055, AD-214, AZD5055, LTI-03, CSL312, GB0139, PLN-74809, ENV-101, Pamrevlumab, BI-1015550, and others are expected to have a significant impact on the Idiopathic Pulmonary Fibrosis market in the coming years.   
• In July 2021, FibroGen announced that FG-3019, the Company’s human monoclonal antibody against connective tissue growth factor (CTGF), has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of idiopathic pulmonary fibrosis (IPF).
• In June 2021, Redx Pharma announced that the first healthy volunteer had been dosed in a Phase I clinical evaluating RXC007, investigational oral therapy for Idiopathic Pulmonary Fibrosis (IPF), and other fibrotic, or scarring-related, conditions.
• In May 2021, ImmunoMet Therapeutics announced that the U.S. Food and Drug Administration (FDA) granted fast track status to IM156, a treatment candidate for idiopathic pulmonary fibrosis (IPF).
• In March 2021, MyMD Pharmaceuticals announced that its lead candidate MYMD-1 for the treatment of several autoimmune and age-related disorders, showed promising efficacy in targeting the root causes of inflammation in Idiopathic Pulmonary Fibrosis

Get a Free Sample PDF Report to know more about Idiopathic Pulmonary Fibrosis Pipeline Therapeutic Assessment-

https://www.delveinsight.com/sample-request/idiopathic-pulmonary-fibrosis-pipeline-insight

Emerging Idiopathic Pulmonary Fibrosis Drugs Under Different Phases of Clinical Development Include:

• TXR 1002: Aria Pharmaceuticals
• INS018_055: InSilico Medicine
• AD-214: AdAlta
• AZD5055: AstraZeneca
• LTI-03: Lung Therapeutics
• CSL312: CSL Behring
• GB0139: Galecto Biotech AB
• PLN-74809: Pliant Therapeutics
• ENV-101: Endeavor BioMedicine
• Pamrevlumab: FibroGen
• BI-1015550: Boehringer Ingelheim

Route of Administration

Idiopathic Pulmonary Fibrosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Molecule Type

Products have been categorized under various Molecule types, such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy 

Idiopathic Pulmonary Fibrosis Pipeline Therapeutics Assessment

• Idiopathic Pulmonary Fibrosis Assessment by Product Type
• Idiopathic Pulmonary Fibrosis By Stage and Product Type
• Idiopathic Pulmonary Fibrosis Assessment by Route of Administration
• Idiopathic Pulmonary Fibrosis By Stage and Route of Administration
• Idiopathic Pulmonary Fibrosis Assessment by Molecule Type
• Idiopathic Pulmonary Fibrosis by Stage and Molecule Type

DelveInsight’s Idiopathic Pulmonary Fibrosis Report covers around 80+ products under different phases of clinical development like-

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Idiopathic Pulmonary Fibrosis product details are provided in the report. Download the Idiopathic Pulmonary Fibrosis pipeline report to learn more about the emerging Idiopathic Pulmonary Fibrosis therapies

Some of the key companies in the Idiopathic Pulmonary Fibrosis Therapeutics Market include:

Key companies developing therapies for Idiopathic Pulmonary Fibrosis are – Afferent Pharmaceuticals, Boehringer Ingelheim, Bristol-Myers Squibb, Cipla Inc., F. Hoffmann-La Roche Ltd, FibroGen, Genentech USA Inc., Jubilant Cadista, Merck & Co. Inc., Prometic Life Sciences, Mission Therapeutics, Lung Therapeutics, Theravance Biopharma, Pliant Therapeutics, Vicore Pharma, Galecto Biotech, FibroGen, Kinarus,  Insmed, Avalyn Pharmaceuticals,  Bridge Biotherapeutics, and others.

Idiopathic Pulmonary Fibrosis Pipeline Analysis:

The Idiopathic Pulmonary Fibrosis pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Idiopathic Pulmonary Fibrosis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Idiopathic Pulmonary Fibrosis Treatment.
• Idiopathic Pulmonary Fibrosis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Idiopathic Pulmonary Fibrosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Idiopathic Pulmonary Fibrosis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Idiopathic Pulmonary Fibrosis drugs and therapies

Idiopathic Pulmonary Fibrosis Pipeline Market Drivers

Changing lifestyle patterns and increasing consumption of nicotine products, diverse and extensive pipeline therapies, rise in the number of geriatric population are some of the important factors that are fueling the Idiopathic Pulmonary Fibrosis Market.

Idiopathic Pulmonary Fibrosis Pipeline Market Barriers

However, lack of effective treatment options for severe Idiopathic Pulmonary Fibrosis (IPF) cases, exact Cause of IPF is not fully understood, misdiagnosis of Idiopathic Pulmonary Fibrosis (IPF) and other factors are creating obstacles in the Idiopathic Pulmonary Fibrosis Market growth.

Scope of Idiopathic Pulmonary Fibrosis Pipeline Drug Insight    

• Coverage: Global
• Key Idiopathic Pulmonary Fibrosis Companies: Aria Pharmaceuticals, InSilico Medicine, AdAlta, AstraZeneca, Lung Therapeutics, CSL Behring, Galecto Biotech AB, Pliant Therapeutics, Endeavor BioMedicine, FibroGen, Boehringer Ingelheim, and others
• Key Idiopathic Pulmonary Fibrosis Therapies: TXR 1002, INS018_055, AD-214, AZD5055, LTI-03, CSL312, GB0139, PLN-74809, ENV-101, Pamrevlumab, BI-1015550, and others
• Idiopathic Pulmonary Fibrosis Therapeutic Assessment: Idiopathic Pulmonary Fibrosis current marketed and Idiopathic Pulmonary Fibrosis emerging therapies
• Idiopathic Pulmonary Fibrosis Market Dynamics: Idiopathic Pulmonary Fibrosis market drivers and Idiopathic Pulmonary Fibrosis market barriers 

Request for Sample PDF Report for Idiopathic Pulmonary Fibrosis Pipeline Assessment and clinical trials

Table of Contents

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services